Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab in Moderate to Severe Hidradenitis Suppurativa
2023-505803-22-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Amlitelimab with Placebo (2 arms). Primary endpoint: HiSCR50 response at Week 16. Started Apr 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-505803-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505803-22-00.